News

Press Releases

Press Releases

Press Releases

March 3, 2020
Osmotica to Present at Barclays Global Healthcare Conference 2020
BRIDGEWATER, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present
February 18, 2020
Osmotica to Present at 9th Annual SVB Leerink Global Healthcare Conference
BRIDGEWATER, N.J. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at
January 8, 2020
Osmotica Announces Pricing of Public Offering of Ordinary Shares
BRIDGEWATER, N.J. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricing of its public offering of 6,000,000 ordinary shares at a price to the public of $5.00 per share.
January 6, 2020
Osmotica Announces Proposed Public Offering of Ordinary Shares
BRIDGEWATER, N.J. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 6,000,000 ordinary shares.